This CLE webinar will provide guidance to patent counsel for overcoming §103 rejections for biotech and chemical patents. The panel will review recent judicial and PTAB case law and offer insights to address §103 rejections.
Obviousness can be a major hurdle for patent applicants in securing a patent on inventions. An obviousness determination can be complex, and examiners regularly reject patent claims as obvious under §103 in view of a combination of prior art.
For clients who receive a §103 rejection, counsel’s response should be part of a well thought out strategy that anticipates the possibility of later court and PTO challenges. For example, counsel should craft the response to minimize or eliminate prosecution history estoppel.
Further, in light of the demands of AIA post-grant proceedings, such as post-grant reviews and inter partes reviews, counsel should carefully consider submitting evidence, including comparative data, scientific arguments, and supporting declarations, in the reply to the rejection.
Listen as our authoritative panel of patent attorneys examines how the courts have treated §103 rejections and the USPTO’s guidance on §103 rejections. Based on decades of experience, the panel will offer their own war stories on overcoming §103 rejections. The panel will also discuss the distinct challenges for biotech and chemical inventions and best practices for patent counsel to address §103 rejections in biotech and chemical patent applications.
For more information or to register please visit: http://bit.ly/2ymwjPI